Combined AKT and MEK Pathway Blockade in Pre-Clinical Models of Enzalutamide-Resistant Prostate Cancer

Despite recent improvements in patient outcomes using newer androgen receptor (AR) pathway inhibitors, treatment resistance in castrate resistant prostate cancer (CRPC) continues to remain a clinical problem. Co-targeting alternate resistance pathways are of significant interest to treat CRPC and de...

Descripción completa

Detalles Bibliográficos
Autores principales: Toren, Paul, Kim, Soojin, Johnson, Fraser, Zoubeidi, Amina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4821639/
https://www.ncbi.nlm.nih.gov/pubmed/27046225
http://dx.doi.org/10.1371/journal.pone.0152861

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4821639/
https://www.ncbi.nlm.nih.gov/pubmed/27046225
http://dx.doi.org/10.1371/journal.pone.0152861

Ejemplares similares